Company News, Financial News

Net Sales Soar to $2 Billion for Galderma in H1 2023

Company reports double-digit growth for Cetaphil in the international region and success for Alastin Skincare following expansion into Mexico.

Author Image

By: Lianna Albrizio

Associate Editor

Net sales for Galderma soared to $2 billion for the six-month period in the first half of 2023 (H1), up 6.9% year-on-year on a constant currency basis.   Growth is primarily driven by dermatological skincare and therapeutic dermatology. Injectable aesthetics’ growth is attributed to double-digit performance in both neuromodulators and biostimulators, despite softening in the filler market and a high comparative base for the product category in 2022 following a post-COVID rebound.    ...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters